company background image
A009420 logo

Hanall Biopharma KOSE:A009420 Stock Report

Last Price

₩31.95k

Market Cap

₩1.7t

7D

-8.7%

1Y

-15.0%

Updated

20 Dec, 2024

Data

Company Financials +

Hanall Biopharma Co., Ltd.

KOSE:A009420 Stock Report

Market Cap: ₩1.7t

A009420 Stock Overview

A pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. More details

A009420 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Hanall Biopharma Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hanall Biopharma
Historical stock prices
Current Share Price₩31,950.00
52 Week High₩52,000.00
52 Week Low₩28,500.00
Beta0.79
1 Month Change-14.00%
3 Month Change-15.92%
1 Year Change-15.03%
3 Year Change54.35%
5 Year Change-8.84%
Change since IPO3,095.00%

Recent News & Updates

Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Dec 09
Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Oct 14
Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Recent updates

Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Dec 09
Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Oct 14
Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Jun 26
Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

May 22
Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13
There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Feb 12
Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Jan 25
What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 04
Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14
Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Nov 21
Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Shareholder Returns

A009420KR PharmaceuticalsKR Market
7D-8.7%1.5%-1.6%
1Y-15.0%3.2%-9.1%

Return vs Industry: A009420 underperformed the KR Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: A009420 underperformed the KR Market which returned -9.1% over the past year.

Price Volatility

Is A009420's price volatile compared to industry and market?
A009420 volatility
A009420 Average Weekly Movement9.3%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.6%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A009420's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A009420's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
1973309Seungwon Jeongwww.hanall.co.kr

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson’s disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves’ disease; and HL187 and HL186 for immuno-oncology.

Hanall Biopharma Co., Ltd. Fundamentals Summary

How do Hanall Biopharma's earnings and revenue compare to its market cap?
A009420 fundamental statistics
Market cap₩1.66t
Earnings (TTM)-₩6.29b
Revenue (TTM)₩134.24b

12.1x

P/S Ratio

-257.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A009420 income statement (TTM)
Revenue₩134.24b
Cost of Revenue₩65.36b
Gross Profit₩68.88b
Other Expenses₩75.17b
Earnings-₩6.29b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-124.00
Gross Margin51.31%
Net Profit Margin-4.68%
Debt/Equity Ratio0%

How did A009420 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 16:40
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hanall Biopharma Co., Ltd. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Seung Taek OhCape Investment & Securities Co., Ltd.
Ka-hye HongDaishin Securities Co. Ltd.
Jonghyun ParkDAOL Investment & Securities Co., Ltd.